Similar articles

• The morality of biotech patents: differing legal obligations in Europe?

  Ford R. Ford R. Eur Intellect Prop Rev. 1997 Jun;19(6):315-8. Eur Intellect Prop Rev. 1997. PMID: 16538738 No abstract available.
• Biotech patents-business as usual?

  Lawrence S. Lawrence S. Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326. Nat Biotechnol. 2008. PMID: 19060861 No abstract available.
• Impact of gene patenting on R&D and commerce.

  Stott M, Valentine J. Stott M, et al. Nat Biotechnol. 2003 Jul;21(7):729-31; author reply 731. doi: 10.1038/nbt0703-729. Nat Biotechnol. 2003. PMID: 12833081 No abstract available.
• Patents, biotechnology, and hematologic pathology.

  Kettelberger DM, Gambrell P, McClung G. Kettelberger DM, et al. Hematol Pathol. 1992;6(2):99-104. Hematol Pathol. 1992. PMID: 1607346 Review. No abstract available.
• Biotechnology patenting policy in the European Union--as exemplified by the development in Germany.

  Schrell A, Bauser H, Brunner H. Schrell A, et al. Adv Biochem Eng Biotechnol. 2007;107:13-39. doi: 10.1007/10_2007_049. Adv Biochem Eng Biotechnol. 2007. PMID: 17522818 Review.